Malignancies in systemic lupus erythematosus

Mruganka Kale; Rosalind Ramsey-Goldman; Caroline Gordon; Ann E. Clarke; Sasha Bernatsky

doi:10.2217/ijr.13.11

Malignancies in systemic lupus erythematosus

Mruganka Kale, Rosalind Ramsey-Goldman, Caroline Gordon, Ann E. Clarke, Sasha Bernatsky^*

^*Corresponding author for this work

Medicine, Rheumatology Division

Research output: Contribution to journal › Review article › peer-review

Abstract

The purpose of this review is to underline important advancements in the understanding of cancer risks in systemic lupus erythematosus (SLE). In SLE, there is an increased risk of specific kinds of malignancy. For example, the risk of non-Hodgkin's lymphoma is increased several-fold in SLE versus the general population. In addition, heightened risks for lung cancer, thyroid cancer and cervical dysplasia in SLE have been found. Some have postulated that immunosuppressive drugs play a role, as well as other important mediators, such as lupus disease activity itself. One new frontier being explored is the significant finding of a decreased risk of certain nonhematologic cancers (e.g., breast, ovarian, endometrial and prostate) in SLE. The reasons for this are currently under study.

Original language	English (US)
Pages (from-to)	275-280
Number of pages	6
Journal	International Journal of Clinical Rheumatology
Volume	8
Issue number	2
DOIs	https://doi.org/10.2217/ijr.13.11
State	Published - Apr 2013

Keywords

cancer
immunosuppressive drug
malignancy
risk
systemic lupus erythematosus

ASJC Scopus subject areas

Rheumatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/ijr.13.11

Cite this

@article{d8592cfaabdc464089371bc908883d43,

title = "Malignancies in systemic lupus erythematosus",

abstract = "The purpose of this review is to underline important advancements in the understanding of cancer risks in systemic lupus erythematosus (SLE). In SLE, there is an increased risk of specific kinds of malignancy. For example, the risk of non-Hodgkin's lymphoma is increased several-fold in SLE versus the general population. In addition, heightened risks for lung cancer, thyroid cancer and cervical dysplasia in SLE have been found. Some have postulated that immunosuppressive drugs play a role, as well as other important mediators, such as lupus disease activity itself. One new frontier being explored is the significant finding of a decreased risk of certain nonhematologic cancers (e.g., breast, ovarian, endometrial and prostate) in SLE. The reasons for this are currently under study.",

keywords = "cancer, immunosuppressive drug, malignancy, risk, systemic lupus erythematosus",

author = "Mruganka Kale and Rosalind Ramsey-Goldman and Caroline Gordon and Clarke, {Ann E.} and Sasha Bernatsky",

year = "2013",

month = apr,

doi = "10.2217/ijr.13.11",

language = "English (US)",

volume = "8",

pages = "275--280",

journal = "Future Rheumatology",

issn = "1758-4272",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - Malignancies in systemic lupus erythematosus

AU - Kale, Mruganka

AU - Ramsey-Goldman, Rosalind

AU - Gordon, Caroline

AU - Clarke, Ann E.

AU - Bernatsky, Sasha

PY - 2013/4

Y1 - 2013/4

N2 - The purpose of this review is to underline important advancements in the understanding of cancer risks in systemic lupus erythematosus (SLE). In SLE, there is an increased risk of specific kinds of malignancy. For example, the risk of non-Hodgkin's lymphoma is increased several-fold in SLE versus the general population. In addition, heightened risks for lung cancer, thyroid cancer and cervical dysplasia in SLE have been found. Some have postulated that immunosuppressive drugs play a role, as well as other important mediators, such as lupus disease activity itself. One new frontier being explored is the significant finding of a decreased risk of certain nonhematologic cancers (e.g., breast, ovarian, endometrial and prostate) in SLE. The reasons for this are currently under study.

AB - The purpose of this review is to underline important advancements in the understanding of cancer risks in systemic lupus erythematosus (SLE). In SLE, there is an increased risk of specific kinds of malignancy. For example, the risk of non-Hodgkin's lymphoma is increased several-fold in SLE versus the general population. In addition, heightened risks for lung cancer, thyroid cancer and cervical dysplasia in SLE have been found. Some have postulated that immunosuppressive drugs play a role, as well as other important mediators, such as lupus disease activity itself. One new frontier being explored is the significant finding of a decreased risk of certain nonhematologic cancers (e.g., breast, ovarian, endometrial and prostate) in SLE. The reasons for this are currently under study.

KW - cancer

KW - immunosuppressive drug

KW - malignancy

KW - risk

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84875735802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875735802&partnerID=8YFLogxK

U2 - 10.2217/ijr.13.11

DO - 10.2217/ijr.13.11

M3 - Review article

AN - SCOPUS:84875735802

VL - 8

SP - 275

EP - 280

JO - Future Rheumatology

JF - Future Rheumatology

SN - 1758-4272

IS - 2

ER -

Malignancies in systemic lupus erythematosus

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this